FDA approves twice-yearly generic-priced HIV prevention injection, with a VR molecular tool in focus

In June 2024, the U.S. FDA approved Gilead Sciences' lenacapavir for HIV-1 pre-exposure prophylaxis, a capsid inhibitor administered as a subcutaneous injection every six months. Indian drugmakers have pledged to supply generic versions to low- and middle-income countries for roughly $40 per year, potentially reshaping global HIV prevention. The article, written by a researcher, describes using the NexoPeek VR application to examine lenacapavir's binding pocket on the HIV capsid and its hydrogen-bond interactions. The author frames interactive molecular visualization as a complement to the drug's pricing news, aiding understanding of how the compound works.